Bluebird bio on Friday confirmed it has received an unsolicited take-over offer from the Ireland-based investment firm Ayrmid ...

The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s ...

Bluebird City restaurant has opened in Evolv Collection’s South Place hotel as the group refocuses its operations under new ...

Ayrmid has offered to buy bluebird for an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable upon achievement of a net sales milestone, said ...

Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd.

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

You make the news and music from Colorado Public Radio possible. Your active support builds our community, grounds us in ...

(NASDAQ:BLUE – Get Free Report) had its target price reduced by Barclays from $40.00 to $8.00 in a report released on ...

Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. | A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio, and the company's board ...

Barclays lowered the firm’s price target on Bluebird Bio (BLUE) to $8 from $40 and keeps an Overweight rating on the shares. The company ...